ExpreS2ion announces financial results for the fourth quarter and full-year 2022
Hørsholm, Denmark, February 9, 2023– ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces its fourth quarter and full-year financial results for 2022. The report is available as an attachment and on ExpreS2ion's website (www.expres2ionbio.com). Below is a summary of the report.CEO Bent U. Frandsen comments “In 2022, ExpreS[2]ion continued its journey towards becoming a stronger and more pipeline-driven biotechnology company with several high-value assets. Excellent progress was achieved in our leading development projects for COVID-19 and breast cancer, and our ExpreS2™ platform